Brief: Vaxxinity Announces First Subjects Dosed In Phase 1 Clinical Trial Of Vxx-401, Investigational Anti-Pcsk9 Vaccine To Treat Hypercholesterolemia
20/03/2023 12:27
March 20 (Reuters) - Vaxxinity Inc VAXX.O :
* VAXXINITY ANNOUNCES FIRST SUBJECTS DOSED IN PHASE 1
CLINICAL
TRIAL OF VXX-401, INVESTIGATIONAL ANTI-PCSK9 VACCINE TO TREAT
HYPERCHOLESTEROLEMIA
Source text for Eikon: ID:nGNXcgXKB5
Further company coverage: VAXX.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Vaxxinity
See all newsU.S. STOCKS ON THE MOVE-EV stocks, Salesforce, Verizon
Brief: Vaxxinity Announces Intention To Voluntarily Delist And Deregister Its Class A Common Stock
Brief: Vaxxinity Announces Intention To Voluntarily Delist And Deregister Its Class A Common Stock
Brief: Vaxxinity Q4 Net Income USD -11.392 Million
Vaxxinity Inc expected to post a loss of 10 cents a share - Earnings Preview